Searched for
SUN PHARMA TARGET PRICE
Summer Solstice 2026 June 21: Why it’s the longest day of the year, its significance, science behind it, and how it affects youSummer Solstice 2026: Today, 21 June 2026, marks the Summer Solstice, the longest day of the year in the Northern Hemisphere. Caused by Ear...- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- June 21 Cosmic Forecast: How Sun in Cancer and Mars in Taurus Will Impact Every Zodiac SignJune 21, 2026 brings one of the most significant astrological shifts of the month as the Sun enters Cancer and Mars moves into Taurus on th...
- When Is Summer Solstice 2026? Date, Time, Spiritual Meaning and Zodiac Signs Most AffectedThe Summer Solstice will occur on June 21, 2026, marking the official start of summer in the Northern Hemisphere and bringing the longest d...
- Stock Radar: Trent broke out from an inverted head & shoulder pattern; time to buy?Trent Ltd stock has broken out of a bullish reversal pattern. Experts recommend buying the stock for a target of Rs 3,500 in the next one t...
- Sensex rises 254 points, Nifty closes above 24,150; IndiGo, Trent among top gainersIndian stock markets closed higher on Thursday, with Sensex and Nifty extending gains for a fifth consecutive session. Despite a hawkish US...
- Robinhood stock soars despite layoffs – Why Wall Street is bullishRobinhood shares rallied after announcing a 10% workforce reduction, as investors viewed the move as a cost-efficiency strategy. Strong tra...
- API prices fall as West Asia tensions ease, boosting Indian pharma sectorPrices for active pharmaceutical ingredients have seen a decline of five to ten percent, thanks to the calming geopolitical climate in West...
- Stock Radar: MRPL bounces back after forming double bottom formation; stock still down 25% from highs – should you buy?Mangalore Refinery and Petrochemicals Ltd stock is showing positive signals. A double bottom formation on daily charts indicates a potentia...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Nomura raises Adani Ports share price target by 12%. Here are 3 major reasons whyNomura has raised its target price on Adani Ports and Special Economic Zone to Rs 2,080 from Rs 1,850, while retaining its Buy rating. The ...
- Buy, Sell or Hold: RIL remains Morgan Stanley's top pick; remains underweight on Oil IndiaBrokerages remain selective on India's energy sector, favouring companies with strong growth drivers and attractive valuations. Morgan Stan...
- Emerging market bets split as global rate paths divergeInvestors are changing their strategies in emerging markets. Central banks in Indonesia, Hungary, and Poland are making different moves on ...
- PL Capital cuts Nifty target to 26,449, lists 16 high conviction stock picksAmidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...
- Market Trading Guide: Allied Blenders among 2 stock recommendations for FridayDomestic markets recovered modestly on easing oil prices and selective buying in banking and pharma stocks. Analysts have recommended Allie...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
Load More
